NLMSF Logo
(303) 808-3437Donate Now
NLMSF Logo
(303) 808-3437Donate Now
Research Publication

General LMS Research Highlights

Curated publications, research updates, clinical trials, and educational links relevant to the broader sarcoma community.

Research Grants Clinical Trials Publications Education

NLMSF Research Grants

2026–2027 Research Grant Announcement

LOI deadline: April 15, 2025

The National Leiomyosarcoma Foundation (NLMSF) invites letters of intent (LOIs) for pilot studies to launch new research trajectories in LMS, with a focus on basic and translational science. Clinical interventional trials are out of scope.

  • Total award: $50,000 per year for 2 years (indirects ≤ 10%).
  • Scope includes biomarkers, imaging, computational biology, radiomics, and lab‑based translational studies.
  • Human sample studies require IRB approval (or waiver) prior to award.

Submission contacts: matthew.hemming@umassmemorial.org and alessandra.maleddu@cuanschutz.edu

Research Updates

Identification of a novel minor-groove DNA binder that represses mitochondrial gene expression and induces apoptosis in highly aggressive leiomyosarcoma cells

New research article (PubMed).

View on PubMedPatient-friendly summary

Stereotactic radiosurgery outcomes for brain metastases from sarcoma primaries (2025)

International multicenter analysis; Cancer (2025).

Leiomyosarcoma: Therapeutic approaches and future directions (2025)

Hematology/Oncology Clinics of North America.

Trabectedin + Olaparib Phase II trial in advanced sarcoma (2025)

Clin Cancer Res. Online ahead of print.

For additional items, see our News Tracker and Clinical Trials pages.

Clinical Trials & Education

Lurbinectedin + doxorubicin vs doxorubicin

Metastatic LMS — Study overview

Leiomyosarcoma — Continuing Education

NCBI Bookshelf

Therapeutic advances in leiomyosarcoma

Frontiers in Oncology

Annamycin in soft tissue sarcoma lung metastases

Phase 1b/2 MB‑107: 59.4% clinical benefit rate (n=36), median OS 13.5 months (330 mg/m²). Patients achieving response or SD after 2 cycles had median OS 19.7 months; no cardiotoxicity.

Research Library (By Year)

2025

Clinical outcomes following stereotactic radiosurgery for brain metastases from sarcoma primaries (Cancer, 2025)Leiomyosarcoma: Therapeutic Approaches and Future Directions (H/O Clinics of North America)Emerging Role of Blood‑based Biomarkers in Sarcomas (H/O Clinics of North America)
MicroRNAs in Uterine Leiomyosarcoma: From Molecular Mechanisms to Clinical Applications (Int J Mol Sci. 2025;26(22):10952)

Kourti A, Kalogiannidis I, Makedou K, Georgiou E. doi: 10.3390/ijms262210952. Full research publication available via PubMed Central.

Trabectedin + Olaparib in Advanced Sarcoma — Phase II Multicenter Trial (Clin Cancer Res)Histology‑driven tailoring of surgery in retroperitoneal STS (BJS Open, 2025)Myxoid Leiomyosarcoma of the Uterus — Case Report (Oncology Letters, 2025)

2024

Doxorubicin–Trabectedin in Leiomyosarcoma (NEJM correspondence)Lurbinectedin + doxorubicin vs doxorubicin alone — metastatic LMS (JCO TPS11590)Leiomyosarcoma of the abdomen and retroperitoneum — systematic review (Frontiers in Surgery)Phase Ib: Doxorubicin, Dacarbazine, and Nivolumab (GEIS) — LMS (JCO)Immunotherapy in Sarcoma: Current Data and Promising Strategies (ASCO Educational Book)Developing Novel Genomic Risk Stratification Models in STS & ULMS (Clin Cancer Res)Leiomyosarcoma — Continuing Education Activity (NCBI Bookshelf)

2023

Therapeutic advances in leiomyosarcoma (Frontiers in Oncology)Targeting Molecular and Immunologic Features of LMS (Cancers)Sequential RB and DNA synthesis pathway targeting strategy (MD Anderson)Not All Leiomyosarcomas Are the Same: classification (Springer)Trabectedin long‑term disease control retrospective studyEmerging Trends in Immunotherapy for Adult Sarcomas (The Oncologist)

2022

What Clinical Trials Are Needed for Treatment of Leiomyosarcoma?Molecular subtypes of leiomyosarcoma: Moving toward a consensusLandmark Series: A Review of Landmark Studies in the Treatment of Primary Localized Retroperitoneal SarcomaPhase II Clinical Trial of Eribulin–Gemcitabine Combination Therapy in Advanced Liposarcoma or LeiomyosarcomaA phase Ib/II study of lenvatinib + eribulin (LEADER): Efficacy updatesRetroperitoneal LMS Nomogram ModelSounding the Alarm on Leiomyosarcoma Recurrence: Role of ctDNASurgical management strategy for LMS of IVCPreclinical Modeling of LMS Identifies Susceptibility to Transcriptional CDK InhibitorsPreoperative Differentiation of Uterine Leiomyomas and Leiomyosarcomas

2021

NLMSF–SPAEN publication on evidence-based unmet needs in LMS research and treatment

Featured publication (2021) — A collaborative paper identifying critical gaps and priorities to accelerate progress in leiomyosarcoma research and care.

Surgical resection of LMS of the IVC: case series + reviewRelationships between highly recurrent tumor suppressor alterations in 489 LMSLarge-scale multiomic analysis suggests mechanisms of resistance to immunotherapy in LMSMultiomic analysis reveals distinct profiles of uterine and non-uterine LMS

Additional 2021 resources:

Hexosamine biosynthesis pathway prognostic relevanceCompanion article
Dr. Matt Hemming's PresentationDetection of circulating tumor DNA in progressive LMSDr. Brian Crompton and Dr. Jonathan Trent PresentationsctDNA in LMS — molecular analysis of 73 patients

2020

Nutrition & gut microbiome — current explorationsCombination chemotherapy regimens — expert reviewGenomic profiling of primary histiocytic sarcomaGenomic landscape of uterine sarcomas (prospective sequencing)NBTXR3 activity in STS

2019

Genomic Evolutionary Patterns of LMS & LPS (Clin Cancer Res)BRCA1/2 functional loss as a targetable subset in LMSctDNA detection in progressive LMS

2018

Soft Tissue and Uterine Leiomyosarcoma (review)Cutaneous LMS on the trunk — aggressive course case & reviewIfosfamide and doxorubicin in advanced LMS

This library highlights selections from a larger set. For the complete verbatim archive, see the section below.

Full Research Archive (Verbatim)

Imported exactly as provided to ensure every original item appears. Collapsed by default for readability.

View full archive

The full verbatim archive includes grant announcements, key dates, and year-by-year publications (2025–2018) with links. Content is maintained by NLMSF. For the curated Research Library by year, scroll to the section above.

To add the complete HTML archive here, replace this placeholder with the full content or use the Research Library (By Year) links above for all curated items.